JP2006506348A - ２−ピロリジン−２−イル−［１，３，４］−オキサジアゾール−誘導体及びこれを抗うつ剤として使用する方法 - Google Patents

２−ピロリジン−２−イル−［１，３，４］−オキサジアゾール−誘導体及びこれを抗うつ剤として使用する方法 Download PDF

Info

Publication number
JP2006506348A
JP2006506348A JP2004535155A JP2004535155A JP2006506348A JP 2006506348 A JP2006506348 A JP 2006506348A JP 2004535155 A JP2004535155 A JP 2004535155A JP 2004535155 A JP2004535155 A JP 2004535155A JP 2006506348 A JP2006506348 A JP 2006506348A
Authority
JP
Japan
Prior art keywords
phenyl
pyrrolidin
oxadiazol
alkyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004535155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506348A5 (enExample
Inventor
ヘンニース・ハーゲン−ハインリヒ
ズンダーマン・コリンナ
ブシュマン・ヘルムート
ズンダーマン・ベルント
Original Assignee
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング filed Critical グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング
Publication of JP2006506348A publication Critical patent/JP2006506348A/ja
Publication of JP2006506348A5 publication Critical patent/JP2006506348A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2004535155A 2002-08-30 2003-08-25 ２−ピロリジン−２−イル−［１，３，４］−オキサジアゾール−誘導体及びこれを抗うつ剤として使用する方法 Pending JP2006506348A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10240818A DE10240818A1 (de) 2002-08-30 2002-08-30 Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
PCT/EP2003/009390 WO2004024725A1 (de) 2002-08-30 2003-08-25 2-pyrrolidin-2-yl-[1,3,4]-oxadiazol-derivate und ihre verwendung als antidepressiva

Publications (2)

Publication Number Publication Date
JP2006506348A true JP2006506348A (ja) 2006-02-23
JP2006506348A5 JP2006506348A5 (enExample) 2010-05-27

Family

ID=31983895

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004535155A Pending JP2006506348A (ja) 2002-08-30 2003-08-25 ２−ピロリジン−２−イル−［１，３，４］−オキサジアゾール−誘導体及びこれを抗うつ剤として使用する方法

Country Status (18)

Country Link
US (1) US7105538B2 (enExample)
EP (1) EP1532141B1 (enExample)
JP (1) JP2006506348A (enExample)
CN (1) CN100390168C (enExample)
AR (1) AR041093A1 (enExample)
AT (1) ATE484503T1 (enExample)
CA (1) CA2497078A1 (enExample)
CY (1) CY1110913T1 (enExample)
DE (2) DE10240818A1 (enExample)
DK (1) DK1532141T3 (enExample)
ES (1) ES2351119T3 (enExample)
MX (1) MXPA05002298A (enExample)
PE (1) PE20040983A1 (enExample)
PL (1) PL375627A1 (enExample)
PT (1) PT1532141E (enExample)
RU (1) RU2324694C2 (enExample)
SI (1) SI1532141T1 (enExample)
WO (1) WO2004024725A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533157A (ja) * 2012-10-10 2015-11-19 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ［オルトビ−（ヘテロ−）アリール］−［２−（メタビ−（ヘテロ−）アリール）−ピロリジン−１−イル］−メタノン誘導体であるオレキシン受容体アンタゴニスト

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2291080E (pt) 2008-05-14 2015-10-30 Scripps Research Inst Novos modelamodeladores dos recetores da esfingosina fosfato
RU2417995C1 (ru) * 2009-09-21 2011-05-10 Государственное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ГОУ ВПО "КубГТУ") Способ получения 3-(2-замещенных-1,3-оксазол-4-ил)пиридин-2(1н)-онов
CN103420998A (zh) * 2012-05-16 2013-12-04 苏州爱斯鹏药物研发有限责任公司 一种新型噁二唑衍生物的合成方法
DK2855453T3 (en) 2012-06-04 2017-02-06 Actelion Pharmaceuticals Ltd Benzimidazol-proline derivatives
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
CN105051040A (zh) * 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
CN103333165B (zh) * 2013-07-01 2016-02-24 河南理工大学 2-苯基-5-(3,4-二甲基)吡咯基-1,3,4-噁二唑及制备方法
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
CN111978311B (zh) * 2019-05-21 2024-05-31 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS49109379A (enExample) * 1973-02-01 1974-10-17
US4784998A (en) * 1987-04-06 1988-11-15 Bristol-Myers Company 1,3,4-oxadiazole pyschotropic compounds
WO2001004116A2 (en) * 1999-07-09 2001-01-18 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic pyrrolidines and piperidines, and related compositions containing them
JP2001247569A (ja) * 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
JP2001518084A (ja) * 1997-03-10 2001-10-09 ビーエーエスエフ アクチェンゲゼルシャフト Ｃ−末端にカルボニル基及び複素環基を有するドラスタチン１５誘導体
WO2002002554A1 (en) * 2000-06-30 2002-01-10 F. Hoffmann-La Roche Ag Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS49109379A (enExample) * 1973-02-01 1974-10-17
US4784998A (en) * 1987-04-06 1988-11-15 Bristol-Myers Company 1,3,4-oxadiazole pyschotropic compounds
JP2001518084A (ja) * 1997-03-10 2001-10-09 ビーエーエスエフ アクチェンゲゼルシャフト Ｃ−末端にカルボニル基及び複素環基を有するドラスタチン１５誘導体
WO2001004116A2 (en) * 1999-07-09 2001-01-18 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic pyrrolidines and piperidines, and related compositions containing them
JP2001247569A (ja) * 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
WO2002002554A1 (en) * 2000-06-30 2002-01-10 F. Hoffmann-La Roche Ag Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533157A (ja) * 2012-10-10 2015-11-19 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ［オルトビ−（ヘテロ−）アリール］−［２−（メタビ−（ヘテロ−）アリール）−ピロリジン−１−イル］−メタノン誘導体であるオレキシン受容体アンタゴニスト

Also Published As

Publication number Publication date
MXPA05002298A (es) 2005-06-08
PT1532141E (pt) 2010-11-02
EP1532141B1 (de) 2010-10-13
SI1532141T1 (sl) 2010-12-31
DK1532141T3 (da) 2010-11-22
CN1678609A (zh) 2005-10-05
ES2351119T3 (es) 2011-01-31
US20050187260A1 (en) 2005-08-25
CA2497078A1 (en) 2004-03-25
US7105538B2 (en) 2006-09-12
PE20040983A1 (es) 2005-01-12
AR041093A1 (es) 2005-05-04
AU2003264097A1 (en) 2004-04-30
EP1532141A1 (de) 2005-05-25
PL375627A1 (en) 2005-12-12
RU2324694C2 (ru) 2008-05-20
RU2005109164A (ru) 2006-01-20
DE50313185D1 (de) 2010-11-25
DE10240818A1 (de) 2004-05-13
CY1110913T1 (el) 2015-06-10
CN100390168C (zh) 2008-05-28
ATE484503T1 (de) 2010-10-15
WO2004024725A1 (de) 2004-03-25

Similar Documents

Publication Publication Date Title
JP5423675B2 (ja) アゾール化合物
TW201106863A (en) Carboxylic acid-containing compounds, derivatives thereof, and related methods of use
CA2601709A1 (en) Beta-lactamylalkanoic acids
WO2005068448A1 (en) Sulfonamides antagonising n-type calcium channels
RU2333200C2 (ru) Азотсодержащие гетероциклические производные, содержащие 2,6-дизамещенный стирил
US7105538B2 (en) 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants
EP1441718B1 (en) Use of carbinols for the treatment of neuropathic dysfunction
EP1988075A1 (en) Pyrrole derivative or salt thereof
TW201136922A (en) New oxadiazole derivatives
AU6497200A (en) Acyclic and cyclic amine derivatives
FR2930939A1 (fr) Derives de pyrrole, leur preparation et leur application en therapeutique
EP2324015A2 (fr) Derives de thiophene-2-carboxamide, leur preparation et leur application en therapeutique
EP1202970A1 (en) Cyclic amine derivatives for the treatment of neurological diseases
EP1196400A1 (en) Amino-alkyl derivatives
US20020107241A1 (en) N-heterocyclic derivatives
EP2283008B1 (fr) Derives de 4,5-diphenylepyrrole-2-ylcarboxamide, leur preparation et leur utilisation comme antagonistes des recepteurs cb1 des cannabinoides
CN118119612A (zh) 新化合物和包含其的药物组合物
AU2013206201A1 (en) Beta-lactamylalkanoic acids for treating premenstrual disorders

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20060814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060814

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20091111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100305

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100312

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100407

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100518

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100525